Filing Details

Accession Number:
0000899243-17-017895
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-07-05 20:26:00
Reporting Period:
2017-07-05
Filing Date:
2017-07-05
Accepted Time:
2017-07-05 20:26:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1420565 Aileron Therapeutics Inc ALRN () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1112278 Cvf, Llc 222 North Lasalle Street
Suite 2000
Chicago IL 60601
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-07-05 536,180 $0.00 536,180 No 4 C Direct
Common Stock Acquisiton 2017-07-05 180,000 $15.00 716,180 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series E-3 Preferred Stock Disposition 2017-07-05 4,411,765 $0.00 443,973 $0.00
Common Stock Series F Preferred Stock Disposition 2017-07-05 916,262 $0.00 92,207 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  2. Richard H. Robb, manager of CVF, LLC, exercises voting and investment power with respect to shares held by CVF, LLC. Mr. Robb disclaims beneficial ownership of all shares held by CVF, LLC, except to the extent of his pecuniary interest therein.